About: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options
Creator	Bhella, David Touyz, Rhian Wang, D'acquisto, Fulvio Madhur, Meena Dao, Wen Berry, Colin Crea, Filippo Guzik, Tomasz Kreutz, Reinhold Marian, Ali Murray, Eleanor Tomaszewski, Maciej Maffia, Pasquale Thomson, Emma Dimarco, Anthony Guzik, Bartlomiej Marelli-Berg, Federica Mcinnes, Iain Mohiddin, Saidi Nicklin, Stuart Nosalski, Ryszard Patel, Vimal Sagliocco, Orlando Savvatis, Kostas
source	Medline; PMC
abstract	The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) —a homologue of ACE—to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin–angiotensin–aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1093/cvr/cvaa106
bibo:pmid	32352535
has license	no-cc
sha1sum (hex)	d09e194306a1d65ccf7289138eb5b4b9e0f30a7a
schema:url	https://doi.org/10.1093/cvr/cvaa106
resource representing a document's title	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options
has PubMed Central identifier	PMC7197627
has PubMed identifier	32352535
schema:publication	Cardiovasc Res
resource representing a document's body	covid:d09e194306a1d65ccf7289138eb5b4b9e0f30a7a#body_text
is schema:about of	named entity 'THEIR' named entity 'CARDIOVASCULAR SYSTEM' named entity 'S PROTEIN' named entity 'INITIAL' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'IL-7' named entity 'INCREASE' named entity 'TRANSMEMBRANE' named entity 'MIGHT BE' named entity 'PROGNOSIS' named entity 'INCLUDE' named entity 'MONITORING' named entity 'EVALUATION' named entity 'HOSPITALIZATION' named entity 'MACROPHAGES' named entity 'INVASION' named entity 'COMORBIDITIES' named entity 'ACE inhibitors' named entity 'endothelial dysfunction' named entity 'myocarditis' named entity 'DIC' named entity 'cardiomyocytes' named entity 'chronic pulmonary disease' named entity 'cardiac damage' named entity 'acute respiratory distress syndrome' named entity 'comorbidities' named entity 'SARS-CoV-2' named entity 'creatine kinase' named entity 'COVID' named entity 'cardiovascular disease' named entity 'macrophages' named entity 'transmembrane' named entity 'COVID' named entity 'pneumomediastinum' named entity 'circulatory failure' named entity 'clinical trials' named entity 'IL-6 receptor' named entity 'Ebola' named entity 'viral entry' named entity 'diagnostic testing' named entity 'IL-18' named entity 'RAAS' named entity 'serine protease' named entity 'clinical presentation' named entity 'acute myocarditis' named entity 'Pneumonia' named entity 'long-term' named entity 'cytokine storm' named entity 'comorbidities' named entity 'innate immune response' named entity 'CRCs' named entity 'myocardial infarction' named entity 'ACE2' named entity 'China' named entity 'COVID-19' named entity 'COVID' named entity 'RAAS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software